Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
| Code | CSB-RA262034A0HU |
| Size | US$210 |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
| Application | Recommended Dilution |
|---|---|
| WB | 1:500-1:5000 |
| FC | 1:20-1:200 |
The recombinant monoclonal antibody targeting LGR5 was generated using protein and DNA recombinant technologies. Initially, a synthesized peptide derived from human LGR5 was used to immunize mice. After that, the spleen was extracted from the immunized mice under sterile conditions, and total RNA was extracted from the spleen cells. The cDNA synthesized from RNA reverse transcription served as the template for PCR amplification of the LGR5 antibody gene. The LGR5 antibody gene was then cloned into a vector, which was transfected into host cells for expression. The LGR5 recombinant monoclonal antibody was purified from the supernatant of the host cell culture using affinity chromatography and was rigorously tested for its ability to detect human and rat LGR5 protein in ELISA, WB, and FC experiments.
The LGR5 protein is a cell surface receptor that is involved in signaling pathways important for maintaining the self-renewal capacity of stem cells and for regulating their differentiation into specialized cell types. LGR5 binds to R-spondin, which activates the Wnt signaling pathway, leading to the activation of downstream transcription factors such as β-catenin, promoting the expression of genes involved in cell proliferation and survival. Dysregulation of LGR5 signaling has been implicated in various diseases, including cancer, where LGR5 has been identified as a marker of cancer stem cells in several tumor types.
There are currently no reviews for this product.
